[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hepatocyte Growth Factor - Pipeline Review, H1 2020

April 2020 | 80 pages | ID: HFCC9D28EDA1EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Hepatocyte Growth Factor - Pipeline Review, H1 2020

SUMMARY

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules. The latest report Hepatocyte Growth Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 4 and 3 respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Respiratory which include indications Amyotrophic Lateral Sclerosis, Colorectal Cancer, Critical Limb Ischemia, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Advanced Malignancy, Alzheimer's Disease, Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lung Injury, Lymphedema, Lymphoma, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuromuscular Disorders, Non-Small Cell Lung Cancer, Parkinson's Disease, Peripheral Artery Occlusive Disease (PAOD), Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar and Thromboangiitis obliterans (Buerger disease).

Furthermore, this report also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
Athira Pharma Inc
Beijing SH Bio-Tech Corp
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
Ad-HGF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDX-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Feb 04, 2020: AnGes, Inc. initiated Phase 2b study in the U.S. in patients with lower limb ischemic ulcers
Dec 27, 2019: Molecular Partners receives orphan drug designation for MP0250 for multiple myeloma
Dec 20, 2019: Genopis, plasmid DNA manufacturer in San Diego, to Launch GMP contract manufacturing business
Dec 12, 2019: Molecular Partners provides update on its Multiple Myeloma drug candidate MP-0250 at R&D Day
Dec 09, 2019: Athira Pharma presents positive data for NDX-1017 in Alzheimer's patients at 2019 clinical trials on Alzheimer's disease (CTAD) conference
Dec 07, 2019: Molecular Partners presents updated results of MP0250 in patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting
Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference
Oct 07, 2019: Helixmith shows long-term safety and efficacy of VM202 for painful DPN patients in DPN phase 3-1b extension study
Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients
Sep 23, 2019: Helixmith: Topline results of DPN Phase III study
Sep 04, 2019: Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy product
Aug 02, 2019: Helixmith unveils results for neuromuscular disease treatment
Jul 16, 2019: Athira Pharma presents preliminary results from phase 1 trial of NDX-1017 at Alzheimer's Association International Conference 2019 (AAIC)
May 27, 2019: Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment
May 01, 2019: Athira Pharma announces appointment of Dr. Hans J. Moebius as chief medical officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AnGes Inc, H1 2020
Pipeline by Athira Pharma Inc, H1 2020
Pipeline by Beijing SH Bio-Tech Corp, H1 2020
Pipeline by Helixmith Co Ltd, H1 2020
Pipeline by i2 Pharmaceuticals Inc, H1 2020
Pipeline by Kringle Pharma Inc, H1 2020
Pipeline by Minerva Biotechnologies Corp, H1 2020
Pipeline by Molecular Partners AG, H1 2020
Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
Pipeline by Yooyoung Pharm Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AnGes Inc
Athira Pharma Inc
Beijing SH Bio-Tech Corp
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd


More Publications